As a Food and Drug Administration (FDA)-approved second-generation ALK inhibitor, LDK378 exhibit STING-dependent anti-inflammatory effect in innate immune cells that rendered mice more resistant to lethal sepsis. This evidence concerns the gene STING1 and Sepsis.